Tissue Regenix Group PLC First delivery of OrthoPure(R) XT (1941H)
December 02 2020 - 1:00AM
UK Regulatory
TIDMTRX
RNS Number : 1941H
Tissue Regenix Group PLC
02 December 2020
Tissue Regenix Group plc
First delivery of OrthoPure(R) XT
Leeds, 2 December 2020 - Tissue Regenix Group (AIM:TRX) (the
"Group"), the regenerative medical devices company, announces that
its first delivery of OrthoPure(R) XT has taken place with
additional shipments expected in early 2021.
OrthoPure(R) XT is a decellularized porcine tendon, developed
using the Group's patented dCELL(R) technology. It was granted CE
Mark approval in June 2020 for the reconstruction of knee ligaments
to restore function and stability.
In August 2020, the Company announced its first distribution
agreement, focused on the UK market, with a speciality supplier of
orthopaedic and biologic products. The Group has since targeted key
European markets including securing an additional distribution
partner in Poland. The Group is currently engaged in a number of
discussions with potential partners in other geographies.
Daniel Lee, Chief Executive Officer, Tissue Regenix Group,
commented: "Our plan is to establish an initial distribution
network for OrthoPure(R) XT and expand as procedural levels return.
This will be a key product for the Group in Europe and highlights
the need, and demand, for biologic solutions outside of the current
US market. It is a testament to the work of our processing and
commercial teams that we have secured distribution agreements and
delivery of the product has remained on-track despite the
challenges presented during 2020."
For more information:
Tissue Regenix Group plc
Caitlin Pearson Head of Communications Tel: 0330 430 3073
------------------------------------------ ---------------------
Stifel Nicolaus Europe Limited (Nominated Tel: 0207 710 7600
Adviser and Broker)
Ben Maddison / Alex Price
------------------------------------------ ---------------------
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R) ') technology removes DNA and other cellular material
from animal and human soft tissue leaving an acellular tissue
scaffold which is not rejected by the patient's body and can then
be used to repair diseased or worn out body parts. Current
applications address many critical clinical needs such as sports
medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopaedic, foot & ankle,
dental, and sports medicine surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDFSWFAFESSEFE
(END) Dow Jones Newswires
December 02, 2020 02:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024